Agreed. The biggest benefit is in doing this better NIT in trials to make recruitment easier and assessment better going forward. This does limit sites that could recruit though.
Maybe there would have been so many late stage failures in NASH had earlier stages used MRE in combination with biomarkers.
News 
Market Data 
Discover 
